Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy.

Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S; Collaborative Organization of RheothRx Evaluation (CORE) Trial Investigators.

Am Heart J. 2007 Oct;154(4):743-50.


Larger infarct size and lower left ventricular ejection fraction (LVEF) contribute to the higher mortality in diabetic patients with ST elevation myocardial infarction.

Ramaraj R.

Am Heart J. 2008 Mar;155(3):e27. doi: 10.1016/j.ahj.2007.11.015. Epub 2008 Jan 18. No abstract available.


Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.

Ezekowitz JA, Armstrong PW, Granger CB, Theroux P, Stebbins A, Kim RJ, Patel MR.

Am Heart J. 2010 Aug;160(2):272-8. doi: 10.1016/j.ahj.2010.05.035.


Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.

Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM.

J Am Coll Cardiol. 1996 Dec;28(7):1661-9.


Prospective identification of myocardial stunning using technetium-99m sestamibi-based measurements of infarct size.

Christian TF, Gitter MJ, Miller TD, Gibbons RJ.

J Am Coll Cardiol. 1997 Dec;30(7):1633-40.


The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.

Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S; CORE Study Investigators.

J Am Coll Cardiol. 2002 Jan 2;39(1):30-6.


Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.

Patel MR, Worthley SG, Stebbins A, Dill T, Rademakers FE, Valeti US, Barsness GW, Van de Werf F, Hamm CW, Armstrong PW, Granger CB, Kim RJ.

JACC Cardiovasc Imaging. 2010 Jan;3(1):52-60. doi: 10.1016/j.jcmg.2009.09.014. Epub 2010 Jan 12. Erratum in: JACC Cardiovasc Imaging. 2010 Jul;3(7):796. Velleti, Uma S [corrected to Valeti, Uma S].


ST-segment analysis to predict infarct size and functional outcome in acute myocardial infarction treated with primary coronary intervention and adjunctive abciximab therapy.

Sciagrà R, Parodi G, Migliorini A, Valenti R, Antoniucci D, Sotgia B, Pupi A.

Am J Cardiol. 2006 Jan 1;97(1):48-54. Epub 2005 Nov 8.


Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.

Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, Gibson CM; TIMI Study Group.

Am J Cardiol. 2009 Aug 15;104(4):475-9. doi: 10.1016/j.amjcard.2009.04.005. Epub 2009 Jun 17.


Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction.

Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger JA.

J Am Coll Cardiol. 1995 Mar 1;25(3):567-73.


Use of a new myocardial centroid for measurement of regional myocardial dysfunction by electron beam computed tomography: comparison with technetium-99m sestamibi infarct size quantification.

Gerber TC, Schmermund A, Reed JE, Rumberger JA, Sheedy PF, Gibbons RJ, Holmes DR, Behrenbeck T.

Invest Radiol. 2001 Apr;36(4):193-203.


Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial).

Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW.

Am J Cardiol. 2007 Jul 15;100(2):206-10. Epub 2007 Jun 4.


Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial.

Timmer JR, Ottervanger JP, de Boer MJ, Boersma E, Grines CL, Westerhout CM, Simes RJ, Granger CB, Zijlstra F; Primary Coronary Angioplasty vs Thrombolysis-2 Trialists Collaborators Group.

Arch Intern Med. 2007 Jul 9;167(13):1353-9.


Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.

Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ.

J Am Coll Cardiol. 1993 Mar 15;21(4):920-5.


Comparison of serial measurements of infarct size and left ventricular ejection fraction by contrast-enhanced cardiac magnetic resonance imaging and electrocardiographic QRS scoring in reperfused anterior ST-elevation myocardial infarction.

Weir RA, Martin TN, Murphy CA, Petrie CJ, Clements S, Steedman T, Dargie HJ, Wagner GS.

J Electrocardiol. 2010 May-Jun;43(3):230-6. doi: 10.1016/j.jelectrocard.2010.01.003. Epub 2010 Feb 1.


Supplemental Content

Support Center